UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 16, 2013
Synergy Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 001-35268 | | 33-0505269 |
(State or other jurisdiction | | (Commission | | IRS Employer |
of incorporation or organization) | | File Number) | | Identification No.) |
420 Lexington Avenue, Suite 1609
New York, NY 10170
(Address of principal executive offices)
Registrant’s telephone number, including area code: (212) 297-0020
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On April 16, 2013, Synergy Pharmaceuticals Inc. (the “Company”) issued a press release announcing the closing of its public offering of 16,375,000 shares of its common stock at a price of $5.50 per share, less underwriting discounts and commissions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 2,456,250 shares of its common stock to cover over-allotments, if any. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are filed with this Current Report on Form 8-K:
Exhibit
No. | | Description |
99.1 | | Press release of Synergy Pharmaceuticals Inc., dated April 16, 2013 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 16, 2013
| SYNERGY PHARMACEUTICALS INC. |
| |
| |
| By: | /s/ Gary S. Jacob |
| | Gary S. Jacob, Ph.D. |
| | President and Chief Executive Officer |
3
